- Home
- / Recursion Pharmaceuticals
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Recursion Pharmaceuticals financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$6.7
2024-10-29
Market Capitalization
$2 B
2024-10-29
Revenue
$74.7 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 23, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 10.2M | 39.8M | 44.6M | 58.8M | 74.7M |
| Cost of goods sold | 48.3M | 42.6M | 45.2M | 71.0M | |
| Gross profit | (8.4M) | 2.0M | 13.6M | 3.7M | |
| Gross profit margin, % | -21.2% | 4.5% | 23.1% | 5.0% | |
| General and administrative expense | 57.7M | 81.6M | 110.8M | 178.2M | 176.6M |
| Operating expense total | 237.3M | 352.0M | 492.6M | 651.9M | |
| EBIT | (182.8M) | (245.7M) | (350.1M) | (479.0M) | (648.1M) |
| EBIT margin, % | -616.7% | -785.3% | -814.1% | -867.9% | |
| Investment income | 19.1M | 15.8M | |||
| Interest expense | 97.0K | 14.2M | |||
| Pre tax profit | (332.1M) | (464.8M) | (644.9M) | ||
| Income tax expense | (4.1M) | (1.1M) | (136.0K) | ||
| Net Income | (186.5M) | (239.5M) | (328.1M) | (463.7M) | (644.8M) |
| EPS | (1.4) | (1.6) | (1.7) | (1.4) |